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The emergence of orthopedic tissue engineering devices as viable clinical solutions demands that the field address significant 
clinical complications associated with the implantation of foreign materials in the body, especially infection. While tissue engi-
neering has focused on the development of methods to regenerate and repair, until recently there has been a relative dearth of 
literature regarding the intersection of tissue engineering and infection. In particular, local delivery of antimicrobials has long 
been of clinical interest, but only recently has that been translated into the realm of tissue engineering. In this perspective, we 
briefly review major modes of local delivery for infection prevention and treatment and discuss possible strategies for preventing 
implant-associated infections. 
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In recent years, the field of tissue engineering has made 
great strides in the development of implantable materials to 
aid in the repair and regeneration of defects due to patholo-
gy or injury. However, infectious complications remain a 
significant source of morbidity, and even mortality, in pa-
tients receiving implants of any kind, and infection rates 
have remained stable over the past decades. The infection 
rate in total hip and knee replacements, a procedure that 
surgeons have extensive experience with and that is per-
formed in a sterile surgical field, is still 1%–2%, and the 
consequent treatment and removal can cause considerable 
morbidity [1,2]. Patients experience pain, loss of productiv-
ity, and decrease in quality of life, and the cost of de-
vice-related infection is estimated to be over $1 billion an-
nually [3]. As orthopedic tissue engineering implants be-
come more clinically implemented, it is reasonable to ex-
pect that they will face similar challenges with respect to 
infectious complications.  
The interaction between bacteria and implanted bio-
materials has long been known and researched, but methods 
to deal with implant-associated infections remain limited. In 
1987, Gristina [4] coined the phrase “race for the surface” 
to describe the competition between cells and bacteria for 
colonization of a surface. Bacteria are inherently favored in 
this race, given their natural ability to colonize both biolog-
ical and non-biological surfaces. Implants that fail to inte-
grate with the host tissue are particularly vulnerable to 
hematogenous seeding from distant infection sites over  
the entire lifetime of the implant. In addition, when free-    
floating planktonic bacteria adhere to a surface, they can 
form biofilms, a hardy microenvironment consisting of pro-
teins, extracellular DNA, and polysaccharides that allow 
bacteria to adhere to surfaces, modulate host immune re-
sponse, and enter a quiescent state of lower metabolic activ-
ity while providing protection against antimicrobial agents 
[5]. Biofilms pose a considerable threat to implants in both 
the acute and chronic setting, as delayed infections can be 
seen several years after implantation [6]. Ideally, implanted 
materials would be toxic specifically to bacterial cells, pre-
vent the adhesion of bacteria, block the phenotypic changes 
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between planktonic and surface-adhered bacteria that result 
in biofilm formation, and promote host tissue integration to 
prevent future colonization with bacteria. While the prob-
lems presented by implant-associated infection are well 
known, there is still a marked lack of progress in the area of 
suitable antimicrobial materials and coatings. Compounding 
the problem, the United States faces rising rates of antibi-
otic-resistant bacterial strains in conjunction with decreas-
ing rates of new antimicrobial drug discovery and marketing 
[7].  
Tissue engineers face several challenges in regards to 
implant-associated infection: (1) develop anti-microbial or 
drug-delivering materials to treat infection while minimiz-
ing antibacterial resistance, (2) combat the growth of bio-
films on the implant, and (3) adapt to the emergence of an-
tibiotic-resistant strains.  
1  Clinical significance and management 
Infection is known to inhibit healing in several tissue types, 
including bone, gastrointestinal epithelium, and cutaneous 
epithelium [8–10]. Physiologic wound healing in response 
to injury occurs in four sequential and timed phases: hemo-
stasis, inflammation, proliferation and repair, and remodel-
ing. Rapid hemostasis occurs via formation of a fibrin clot 
to control bleeding. The injured tissue then recruits inflam-
matory cells through release of pro-inflammatory cytokines 
and growth factors, resulting in the sequential infiltration of 
neutrophils, macrophages, and lymphoctyes. Neutrophils 
play a critical role in controlling infection during this stage 
through production of reactive oxidative species, while 
macrophages clear pro-inflammatory debris. After damaged 
and necrotic tissue has been cleared, the defect is repaired 
through cell proliferation and synthesis of extracellular ma-
trix. Finally, the repaired tissue enters the remodeling phase, 
in which the new tissue is modified to approximate normal 
architecture and strength as closely as possible [11]. Mi-
crobes derail normal wound healing by inducing the affect-
ed area to remain in the inflammatory phase for a prolonged 
period of time. If neutrophils are deficient or inadequate to 
clear bacteria, the presence of bacterial toxins such as lipo-
polysaccharide (LPS) can induce prolonged and elevated 
levels of pro-inflammatory cytokines such as IL-1 and 
TNF-α [11]. Recent studies have shown that the principal 
causative organism for osteomyelitis, Staphylococcus aure-
us, is capable of upregulating production of several 
pro-inflammatory cytokines and inducing resorption of bone 
through RANK-L-mediated osteoclastogenesis, resulting in 
delayed or non-union of the fracture [8,12]. Similarly, for-
mation of bacterial biofilms in a cutaneous wound has been 
shown to result in non-healing in a murine model [10]. In-
terestingly, the wounds were able to re-epithelialize if the 
biofilms were disrupted [10]. Though the mechanisms by 
which infection inhibits healing are just beginning to be 
elucidated, it is obvious that tissue engineering strategies 
will fail without adequate prevention and treatment of in-
fection.  
Currently, orthopedic infections are treated with systemic 
antibiotics, delivered either orally or parenterally. Systemic 
antibiotics can be supplemented with antibiotics delivered 
locally through surgically implanted poly(methyl methacry-
late) (PMMA) beads. Surgical irrigation and debridement 
can also be attempted. Pre-clinical animal studies show that 
early irrigation and debridement, especially in concert with 
antibiotics, may prevent infection, but clinical studies show 
that the failure rate of this approach is high if the site is al-
ready infected [13–16]. If the infection is persistent, remov-
al or replacement of the implant becomes necessary. Im-
plant failure due to infection leaves both the patient and 
physician in a difficult situation: either the implant will not 
be replaced or a new implant must be placed in a contami-
nated area. Solutions to this problem must be two-fold: de-
velopment of materials that deter initial infection from tak-
ing place and materials that are capable of treating already 
existing infection. Local delivery of antimicrobial drugs and 
development of antimicrobial and antibiofilm materials ap-
pears to be a promising approach that has undergone signif-
icant evolution in the past twenty to thirty years. In this 
perspective, we will discuss the major modes of delivery 
that have emerged as possible solutions to the problem of 
infection at implant sites. 
2  Current research in infection 
2.1  Local antibiotic delivery  
Local delivery of antibiotics is an attractive option for the 
prevention of infection for many reasons. First, a large dose 
of antibiotics can be delivered directly to the site of infec-
tion, circumventing the need for areas with good blood flow. 
This is of particular benefit in patients with diabetes, vas-
culopathy, or severe trauma. Second, antibiotic concentra-
tion in the infected area is more likely to be in the therapeu-
tic range, reducing the chance of breeding antibiotic re-
sistant strains. Third, systemic side effects are reduced or 
eliminated since antibiotics should not reach high serum 
concentrations. Considerations that are important when 
evaluating the utility and desirability of a delivery system 
include delivery kinetics and toxicity of the agent locally. 
Generally, sustained release in the therapeutic range for an 
antibiotic/bacterial species combination is desired in order 
to guard against infection until native vascularity can be 
restored. Although high concentrations are useful for treat-
ment, antibiotics can also be toxic to mammalian cells. 
Rathbone et al. [17] demonstrated in vitro that several anti-
biotics commonly used for local delivery in osteomyelitis 
are toxic to osteoblasts. Though there are clear benefits of 
local delivery, there is not yet a consensus on the optimal 
strategy or material that should be employed.  
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Both natural and synthetic materials have been investi-
gated as potential local delivery vehicles. Natural polymers 
such as collagen and chitosan are simply and rapidly loaded 
by soaking them in a solution of the desired antibiotic. Col-
lagen and chitosan both deliver antibiotics in a rapid “burst” 
and release is normally complete within 4 d [18,19]. These 
short-duration release kinetics may not be appropriate for 
surgically implanted delivery vehicles, but they may be 
useful for cutaneous applications, such as infection control 
for burn wounds [20].  
Antibiotic-impregnated PMMA beads have been used 
clinically to deliver antibiotics locally for at least 30 years 
[21]. They are fabricated at the time of implantation by 
mixing the desired antibiotic with PMMA and forming the 
resulting mixture into beads. The “standard” formulation is 
1 g antibiotic mixed into a 40 g package of bone cement, 
although this ratio can be altered. These beads have the ad-
vantage of clinical familiarity, and in vivo studies have in-
dicated that they are effective at eradicating acute infections 
in long bones [22]. In addition, the antibiotic is easily varied 
based on the most likely pathogen. However, since PMMA 
is hydrophobic and non-biodegradable, water does not swell 
the material to release antibiotics, and antibiotics incorpo-
rated into the interior of the bead may not be released. Anti-
biotic release from PMMA may be as low as 25% to 50% of 
total incorporated antibiotic. Release kinetics are widely 
variable between drug classes, and only clindamycin and 
vancomycin can be eluted at therapeutic levels at 28 d [21]. 
Since PMMA is non-biodegradable, a second surgery is 
required to remove the beads once antibiotic elution has 
stopped. Recent studies have also shown that bacterial bio-
films can persist on antibiotic-eluting cement beads when 
implanted into infected areas [23]. In light of these issues, 
biodegradable materials have been investigated as possible 
antibiotic carriers. 
Calcium sulfate is a resorbable ceramic material that has 
been studied as an antibiotic carrier. Similar to PMMA, these 
beads are fabricated by incorporating the antibiotic into a 
calcium sulfate kit, so the antibiotic can be varied easily. 
Tobramycin release has been shown to occur at least up to 
14 d, but levels are sub-therapeutic by 28 d [24]. Resorption 
time from different studies varied from 1 to 6 months and 
can be somewhat tuned by varying the density of calcium 
sulfate crystals [21]. Studies on the efficacy of calcium sul-
fate as a drug-delivery vehicle are widely varied. A 2010 
study shows that calcium sulfate pellets are highly effica-
cious, with resolution of osteomyelitis in all patients fol-
lowed [25]. However, a 2009 retrospective study on the use 
of antibiotic-loaded calcium sulfate in combat-related open 
fractures was less positive, with a 22% rate of osteomyelitis, 
a 25% rate of heterotopic ossification in patients whose 
limbs were not eventually amputated, and over half of pa-
tients experiencing sterile draining sinuses [26]. However, 
in comparison to PMMA, calcium sulfate is a more appro-
priate vehicle for tissue engineering applications since it is 
resorbable and osteoconductive. Unfortunately, calcium 
sulfate lacks sufficient mechanical strength to act as a bone 
scaffold, and the resorption rate of calcium sulfate may be 
too fast for bone regeneration.  
Biodegradable polymers such as poly(lactic acid) (PLA) 
and poly(lactic-co-glycolic acid) (PLGA) have also been 
used to locally deliver antibiotics. Unlike PMMA and cal-
cium sulphate, these polymers can be used in several dif-
ferent forms, including coatings, microspheres [27], and 
electrospun fibers [28]. Release of antibiotics from PLGA 
microspheres, in particular, has been well-characterized, 
and encompasses many different classes of antibiotics such 
as vancomycin [29], nafcillin [30], colistin [27], tobramycin 
[31], and ciprofloxacin [32]. Antibiotic-loaded PLGA mi-
crospheres are a promising vehicle for local delivery given 
the biodegradable nature and biocompatibility of PLGA as 
well as its desirable release kinetics. The release kinetics of 
antibiotics from microspheres are characterized by a burst 
release followed by slow release and a possible smaller, late 
burst. However, the release kinetics are altered to a tri-   
phasic release if the microspheres are incorporated into a 
PMMA construct [27].  
Biodegradable microspheres present an interesting solu-
tion to the problem of antibiotic delivery for tissue engi-
neering applications. Of the vehicles discussed thus far, 
degradable microspheres are unique in that they can easily 
be incorporated into constructs of other materials that are 
capable of bridging to the regeneration of native tissue. Bi-
oactive factors such as vascular endothelial growth factor 
and bone morphogenetic protein-2 have been successfully 
incorporated into and released from biodegradable micro-
spheres as well [33,34]. Composite scaffolds could serve 
multiple functions, such as combining antibiotic and growth 
factor delivery through biodegradable microspheres, and 
mechanical stability and promotion of tissue growth through 
the bulk material. 
2.2  Alternatives to conventional antibiotics 
Although this review has thus far focused on the use of bi-
omaterials as antibiotic carriers for tissue engineering ap-
plications, discussion of local antimicrobials would be in-
complete without mention of alternative antimicrobial 
methods. As mentioned earlier, the development of micro-
bial resistance to conventional antibiotic therapy continues 
to be a major clinical challenge [7]. To address this serious 
issue, research into alternative antimicrobials has gained 
traction in both historically important areas such as silver 
compounds and newer areas, such as nanoparticle formula-
tions and novel synthetic antimicrobial peptides.  
Silver has been an important antimicrobial since ancient 
times, when it was most likely used for chronic wounds and 
ulcers [35]. It has remained a relevant antimicrobial, now 
being used for burn treatment, catheter coatings, and dental 
work [35–37]. Silver causes microbial death by penetrating 
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the cell wall or membrane and interfering with cell replica-
tion and respiration [35,38]. There are several topical for-
mulations of silver used clinically, such as silver nitrate and 
silver sulfadiazine, but silver nanoparticles (NPs) are gain-
ing popularity, even amongst other types of metal and metal 
oxide NPs, as an antimicrobial with far-reaching potential 
since they have been shown to be effective again bacteria, 
viruses, and eukaryotes [39]. Silver NPs have been used as a 
local antimicrobial in coatings of medical devices, wound 
dressings, and textile fabrics [40]. Though silver NPs appear 
to be an attractive solution to the problem of antibiotic re-
sistance, there are reports of silver-resistant bacterial strains 
[37]. More importantly, plasmids that encode for silver re-
sistance also have been shown to often encode antibi-
otic-resistance as well [41]. Increased use of silver NPs may 
lead to an increased selective pressure toward antibiotic- 
resistance bacterial strains through this genetic linkage.  
Antimicrobial peptides (AMPs) are short peptides about 
20–50 residues in length that are found in many species of 
plants and animals, including humans [42]. These peptides 
are generally amphiphilic, allowing them to permeabilize 
bacterial membranes through a combination of electrostatic 
and hydrophobic interactions [42]. AMPs are also generally 
able to distinguish between mammalian and bacterial cell 
membranes due to the predominance of negatively charged 
lipids on the surface of bacterial membranes not seen with 
mammalian cells [42]. An example of a naturally occurring 
antimicrobial peptide is human lactoferrin 1–11 [45]. Syn-
thetic analogues of these naturally-occurring peptides, such 
as arylamide foldamers, have been synthesized and shown 
to be effective against bacteria [42,43]. There has been in-
terest in local delivery of AMPs as an alternative to conven-
tional antibiotics. Several studies have described local de-
livery of AMPs in vitro and in vivo via calcium phosphate 
carrier [44–46]. These studies show that it is possible to 
incorporate and locally release AMPs while retaining anti-
microbial activity, although broad-spectrum AMPs such as 
human lactoferrin 1–11 may not be as potent as convention-
al antibiotics such as gentamicin [44–46]. Shukla et al. [47] 
incorporated a different AMP, ponericin G1, into a de-
gradable polyectrolyte multilayer film that has applications 
as coatings for medical devices and wound healing. Con-
trolled release over 10 d was achieved with tunable release 
profiles and retention of antimicrobial activity [47]. AMPs 
have recently become a popular alternative because it was 
previously believed that resistance to AMPs would be un-
likely given that significant changes to the bacterial cell 
membrane would be required and these peptides have been 
present in bacterial environments for 108 years without 
evolution of significant resistance [48]. However, some 
evolutionary biologists have argued that bacteria would be 
able to evolve resistance mechanisms against these peptides 
when they are used therapeutically due to the creation of a 
circumstance in which there is selective pressure for re-
sistant strains [49]. Recent research has shown that bacteria 
are able to develop resistance in laboratory conditions and 
several mechanisms by which microbes can become re-
sistant to AMPs have been elucidated [50,51]. 
2.3  Antifouling agents 
As the importance of biofilm becomes increasingly recog-
nized, more emphasis is being placed on the development of 
antifouling polymers and biofilm dispersal agents. Biofilms 
are capable of growing on the surface of implanted materi-
als and have even been shown to survive on the surface of 
antibiotic-releasing biomaterials [52,53]. As shown in Fig-
ure 1, Staphylococcus aureus is able to form biofilm even 
on antibiotic-releasing poly(methyl methacrylate) constructs. 
Biofilm dispersal agents can either inhibit the formation 
of biofilm or promote the detachment of biofilm bacteria. 
The dispersal of implant biofilms has several benefits for  
 
 
Figure 1  Staphylococcus aureus biofilm formation on vancomycin-loaded porous poly(methyl methacrylate) constructs at 100×(a) and 400×(b).  
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the patient. The dissolution of the biofilm prevents the im-
plant from being a source of delayed infection, as bacteria 
can detach from the biofilm and seed distant sites. The sur-
face of the implant also becomes more hospitable to native 
cells through lack of competition with bacteria, a distinct 
benefit when tissue integration is the goal. Additionally, 
since biofilm-associated bacteria are known to be much 
more resistant to antibiotics than planktonic bacteria, forc-
ing biofilm bacteria back into their metabolically active 
planktonic phenotype should decrease the local antibiotic 
concentration requirement. Several studies have shown that 
the minimum biofilm eradication concentration (MBEC) for 
bacteria in biofilm is 10–1000 times higher than the mini-
mum inhibitory concentrations (MIC) for planktonic bacte-
ria [54–56]. There is considerable interest in leveraging 
antifouling compounds and materials to enhance the effica-
cy of antimicrobials.  
Cis-2-decenoic acid is a fatty acid messenger produced 
by Pseudomonas aeruginosa that has been shown to pro-
mote the degradation of biofilms and prevent biofilm for-
mation in vitro. It has been shown to be effective at pre-
venting the formation of biofilm by several bacterial species, 
such as Pseudomonas aeruginosa, Klebsiella pneumoniae, 
Proteus mirabilis, Streptococcus pyogenes, Staphylococcus 
aureus, and interestingly, the eukaryote Candida albicans 
[57]. Cis-2-decenoic acid appears to act as a diffusible sig-
naling molecule that allows biofilm organisms to coordinate 
gene expression via cell-cell communication. Jennings et al. 
[58] demonstrated in vitro that antibiotics are more effective 
at preventing biofilm growth when combined with cis-2- 
decenoic acid. Practically, cis-2-decenoic is challenging to 
incorporate into a sustained release local delivery vehicle 
since it is a fatty acid. Chitosan sponges have been investi-
gated as a carrier due to their lipid-binding properties, but 
similar to antibiotic-loaded chitosan, this strategy is limited 
by short-lived release dominated by burst release kinetics.  
Zwitterionic polymers show promise as a novel type of 
coating that can combine antimicrobial action with 
non-fouling of implant materials. Cationic polymers are 
known to be toxic to microbes via interactions with the neg-
atively charged plasma membranes of bacteria, although 
there is concern that these cationic polymers could be toxic 
host cell membranes as well [59,60]. Another significant 
disadvantage of these polymers is that dead bacteria are 
retained through electrostatic interactions. Zwitterionic 
polymers are known to have non-fouling properties and 
have been used extensively to deter the attachment of bacte-
ria and the growth of biofilms. Cheng et al. [61] designed a 
switchable polymer that is toxic to bacteria on contact, then 
switches to a nonfouling zwitterionic coating to release the 
debris and maintain a non-fouled surface. Tan et al. [62] 
have also developed a chitosan derivative with a series of 
substituted quaternary ammonium groups that can be loaded 
into PMMA to decrease fouling by antibiotic-resistant 
Staphylococcus aureus.  
D-amino acids have become increasingly popular as a 
signaling molecule for biofilm dispersal. Several studies 
have noted that D-amino acids can both prevent biofilm 
formation and enhance detachment [63–65]. D-amino acids 
are thought to be synthesized by biofilm bacteria when they 
reach a critical concentration in order to signal bacteria to 
detach and colonize a distant site, and the local concentra-
tion of D-amino acids necessary to signal bacteria to detach 
is on the micromolar order. The most studied D-amino acids 
for biofilm dispersal are D-tyrosine, D-leucine, D-methio- 
nine, and D-tryptophan. Each amino acid has a specific ac-
tivity, but combinations of D-amino acids are found to be 
the most potent against biofilms [64]. D-amino acids are 
inexpensive and have great potential for incorporation into 
local delivery vehicles, contributing to their current preva-
lence in the literature.  
3  Conclusions 
The success of tissue engineering strategies will depend on 
their ability to adequately address infectious complications. 
Regeneration and repair of tissue cannot occur in the pres-
ence of infection, so an effective method of eradicating and 
preventing infections must be developed. The most robust 
strategies will address immediate infection and prevent later 
failure of the implant due to delayed infection by preventing 
biofilm formation. One method to achieve this is to develop 
local delivery vehicles for antibiotics and anti-biofilm 
agents that provide controlled, sustained release, do not 
themselves host biofilm formation, and can accommodate 
the emergence of new antibiotics. 
This work was supported by the Armed Forces Institute of Regenerative 
Medicine (W81XWH-08-2-0032). 
1 Moyad T F, Thornhill T, Estok D. Evaluation and management of the 
infected total hip and knee. Orthopedics, 2008, 31: 581–590 
2 Hanssen A D, Rand J A. Evaluation and treatment of infection at the 
site of a total hip or knee arthroplasty. Instr Course Lect, 1999, 48: 
111–122 
3 Scott R D. National Center for Preparedness, Detection, and Control 
of Infectious Diseases (Centers for Disease Control and Prevention). 
Division of Healthcare Quality Promotion. The direct medical costs 
of healthcare-associated infections in US hospitals and the benefits of 
prevention, 2009 
4 Gristina A G. Biomaterial-centered infection: Microbial adhesion 
versus tissue integration. Science, 1987, 237: 1588–1595 
5 Gristina A G, Shibata Y, Giridhar G, et al. The glycocalyx, biofilm, 
microbes, and resistant infection. Semin Arthroplasty, 1994, 5: 160– 
170 
6 Bayston R, Ashraf W, Barker-Davies R, et al. Biofilm formation by 
propionibacterium acnes on biomaterials in vitro and in vivo: Impact 
on diagnosis and treatment. J Biomed Mater Res, 2007, 81A: 
705–709 
7 Spellberg B, Guidos R, Gilbert D, et al. The epidemic of antibi-
otic-resistant infections: A call to action for the medical community 
from the Infectious Diseases Society of America. Clin Infect Dis, 
2008, 46: 155–164 
 Shah S R, et al.   Chin Sci Bull   December (2013) Vol.58 No.35 4347 
8 Somayaji S N, Ritchie S, Sahraei M, et al. Staphylococcus aureus in-
duces expression of receptor activator of NF-B ligand and prosta-
glandin E2 in infected murine osteoblasts. Infect Immun, 2008, 76: 
5120–5126 
9 Tabel G, Hoa N T, Tarnawski A, et al. Helicobacter pylori infection 
inhibits healing of the wounded duodenal epithelium in vitro. J Lab 
Clin Med, 2003, 142: 421–430 
10 Schierle C F, De la Garza M, Mustoe T A, et al. Staphylococcal bio-
films impair wound healing by delaying reepithelialization in a mu-
rine cutaneous wound model. Wound Repair Regen, 2009, 17: 
354–359 
11 Guo S, DiPietro L A. Factors affecting wound healing. J Dent Res, 
2010, 89: 219–229 
12 Bost K L, Ramp W K, Nicholson N C, et al. Staphylococcus aureus 
infection of mouse or human osteoblasts induces high levels of inter-
leukin-6 and interleukin-12 production. J Infect Dis, 1999, 180: 
1912–1920 
13 Penn-Barwell J G, Murray C K, Wenke J C. Early antibiotics and 
debridement independently reduce infection in an open fracture mod-
el. J Bone Joint Surg Br Vol, 2012, 94B: 107–112   
14 Koyonos L, Zmistowski B, Della Valle C J, et al. Infection control 
rate of irrigation and débridement for periprosthetic joint infection. 
Clin Orthop Rel Res, 2011, 469: 3043–3048 
15 Odum S M, Fehring T K, Lombardi A V, et al. Irrigation and deb-
ridement for periprosthetic infections. J Arthroplasty, 2011, 26: 
114–118 
16 Fehring T K, Odum S M, Berendm K R, et al. Failure of irrigation 
and débridement for early postoperative periprosthetic infection. Clin 
Orthop Rel Res, 2013, 471: 250–257 
17 Rathbone C R, Cross J D, Brown K V, et al. Effect of various con-
centrations of antibiotics on osteogenic cell viability and activity. J 
Orthop Res, 2011, 29: 1070–1074 
18 Wachol-Drewek Z Z, Pfeiffer M M, Schol E E. Comparative investi-
gation of drug delivery of collagen implants saturated in antibiotic 
solutions and a sponge containing gentamicin. Biomaterials, 1996, 17: 
1733–1738 
19 Noel S P, Courtney H, Bumgardner J D, et al. Chitosan films: A po-
tential local drug delivery system for antibiotics. Clin Orthop Rel Res, 
2008, 466: 1377–1382 
20 Mi F L, Wu Y B, Shyu S S, et al. Control of wound infections using a 
bilayer chitosan wound dressing with sustainable antibiotic delivery. 
J Biomed Mater Res, 2001, 59: 438–449 
21 Kent M E, Rapp R P, Smith K M. Antibiotic beads and osteomyelitis: 
Here today, what’s coming tomorrow? Orthopedics, 2006, 29: 599–603 
22 Wenke J C, Owens B D, Svoboda S J, et al. Effectiveness of com-
mercially-available antibiotic-impregnated implants. J Bone Joint 
Surg Br Vol, 2006, 88: 1102–1104 
23 Anagnostakos K, Hitzler P, Pape D, et al. Persistence of bacterial 
growth on antibiotic-loaded beads: Is it actually a problem? Acta Or-
thop, 2008, 79: 302–307 
24 Turner T M, Urban R M, Hall D J, et al. Local and systemic levels of 
tobramycin delivered from calcium sulfate bone graft substitute pel-
lets. Clin Orthop Rel Res, 2005, 437: 97–104 
25 Cai X, Han K, Cong X, et al. The use of calcium sulfate impregnated 
with vancomycin in the treatment of open fractures of long bones: A 
preliminary study. Orthopedics, 2010, 33: 152–157 
26 Helgeson M D, Potter B K, Tucker C J, et al. Antibiotic-impregnated 
calcium sulfate use in combat-related open fractures. Orthopedics, 
2009, 32: 323 
27 Shi M, Kretlow J D, Nguyen A, et al. Antibiotic-releasing porous 
polymethylmethacrylate constructs for osseous space maintenance 
and infection control. Biomaterials, 2010, 31: 4146–4156 
28 Buschle-Diller G, Cooper J, Xie Z, et al. Release of antibiotics from 
electrospun bicomponent fibers. Cellulose, 2007, 14: 553–562 
29 Özalp Y, Özdemir N, Kocagöz S, et al. Controlled release of vanco-
mycin from biodegradable microcapsules. J Microencapsul, 2001, 18: 
89–110 
30 Pillai R R, Somayaji S N, Rabinovich M, et al. Nafcillin-loaded 
PLGA nanoparticles for treatment of osteomyelitis. Biomed Mater, 
2008, 3: 034114 
31 Ambrose C G, Gogola G R, Clyburn T A, et al. Antibiotic micro-
spheres: Preliminary testing for potential treatment of osteomyelitis. 
Clin Orthop Rel Res, 2003, 415: 279–285 
32 Ramchandani M, Robinson D. In vitro and in vivo release of ciprof-
loxacin from PLGA 50:50 implants. J Control Release, 2998, 54: 
167–175 
33 Rui J, Dadsetan M, Runge M B, et al. Controlled release of vascular 
endothelial growth factor using poly-lactic-co-glycolic acid micro-
spheres: In vitro characterization and application in polycaprolactone 
fumarate nerve conduits. Acta Biomater, 2012, 8: 511–518 
34 Ruhé P Q, Boerman O C, Russel F G, et al. Controlled release of 
rhBMP-2 loaded poly(dl-lactic-co-glycolic acid)/calcium phosphate 
cement composites in vivo. J Control Release, 2005, 106: 162–171 
35 Klasen H J. Historical review of the use of silver in the treatement of 
burns. I. Early uses. Burns, 2000, 26: 117–130 
36 Huh A J, Kwon Y J. “Nanoantibiotics”: A new paradigm for treating 
infectious diseases using nanomaterials in the antibiotic resistant era. 
J Control Release, 2011, 156: 128–145 
37 Davis I J, Richards H, Mullany P. Isolation of silver- and antibi-
otic-resistant Enterobacter cloacae from teeth. Oral Microbiol Im-
munol, 2005, 20: 191–194 
38 Feng Q L, Wu J, Chen G Q, et al. A mechanistic study of the anti-
bacterial effect of silver ions on Escherichia coli and Staphylococcus 
aureus. J Biomed Mater, 2000, 52: 662–668 
39 Gong P, Li H, He X, et al. Preparation and antibacterial activity of 
Fe3O4@Ag nanoparticles. Nanotechnology, 2007, 18: 285604 
40 Rai M, Yadav A, Gade A. Silver nanoparticles as a new generation of 
antimicrobials. Biotechnol Adv, 2009, 27: 76–83 
41 Grewal J S, Tiwari R P. Resistance to metal ions and antibiotics in 
Escherichia coli isolated from foodstuffs. J Med Microbiol, 1990, 32: 
223–226 
42 Choi S, Isaacs A, Clements D, et al. De novo design and in vivo ac-
tivity of conformationally restrained antimicrobial peptides. Proc Natl 
Acad Sci USA, 2009, 106: 6968–6973 
43 Liu D, Choi S, Chen B, et al. Nontoxic membrane-active antimicro-
bial arylamide oligomers. Angew Chem Int Ed, 2004, 43: 1158–1162 
44 Kazemzadeh-Narbat M, Kindrachuk J, Duan K, et al. Antimicrobial 
peptides on calcium phosphate-coated titanium for the prevention of 
implant associated infections. Biomaterials, 2010, 31: 9519–9526 
45 Stallman H P, Faber C, Bronckers A L J J, et al. Osteomyelitis pre-
vention in rabbits using antimicrobial peptide hLF1-11- or gentami-
cin-containing calcium phosphate cement. J Antimicrob Chemother, 
2004, 54: 472–476 
46 Stallman H P, de Roo R, Faber C, et al. In vivo release of the antimi-
crobial peptide hlf1-11 from calcium phosphate cement. J Orthop Res, 
2008, 26: 531–538 
47 Shukla A, Fleming K E, Chuang H F, et al. Controlling the release of 
peptide antimicrobial agents from surfaces. Biomaterials, 2010, 31: 
2348–2357 
48 Zasloff M. Antimicrobial peptides of multicellular origin. Nature, 
2002, 415: 389–395 
49 Bell G, Gouyon P H. Arming the enemy: The evolution of resistance 
development and persistence. Microbiology, 2003, 149: 1367–1375 
50 Perron G G, Zasloff M, Bell G. Experimental evolution of resistance 
to an antimicrobial peptide. Proc R Soc B-Biol Sci, 2006, 273: 
251–256  
51 Anaya-López J L, López-Meza J E, Ochoa-Zarzosa A. Bacterial re-
sistance to cationic antimicrobial peptides. Crit Rev Microbiol, 2012, 
38: 1–16 
52 Neut D, van de Belt H, Stokroos I, et al. Biomaterial-associate infec-
tion of gentamicin-loaded PMMA beads in orthopaedic revision sur-
gery. J Antimicrob Chemother, 2001, 47: 885–891 
53 Anagnostakos K, Hitzler P, Pape D, et al. Persistence of bacterial 
growth on antibiotic-loaded beads: Is it actually a problem? Acta Or-
thop, 2008, 79: 302–307 
54 Olson M E, Ceri H, Morck D W, et al. Biofilm bacteria: Formation 
and comparative susceptibility to antibiotics. Can J Vet Res, 2002, 66: 
86–92 
4348 Shah S R, et al.   Chin Sci Bull   December (2013) Vol.58 No.35 
55 Davies D. Understanding biofilm resistance to antibacterial agents. 
Nat Rev Drug Discov, 2003, 2: 114–122 
56 Kirby A E, Garner K, Levin B R. The relative contributions of phys-
ical structure and cell density to the antibiotic susceptibility of bacte-
ria in biofilms. Antimicrob Agents Chemother, 2012, 56: 2967–2975 
57 Davies D G, Marques C N. A fatty acid messenger is responsible for 
inducing dispersion in microbial biofilms. J Bacteriol, 2009, 191: 
1393–1403 
58 Jennings J A, Courtney H S, Haggard W O. Cis-2-decenoic acid in-
hibits s. aureus growth and biofilm in vitro: A pilot study. Clin Or-
thop Rel Res, 2012, 470: 2663–2670 
59 Lü H, Zhang S, Wang B, et al. Toxicity of cationic lipids and cationic 
polymers in gene delivery. J Control Release, 2006, 114: 100–109 
60 Nagamune H, Maeda T, Ohkura K, et al. Evaluation of the cytotoxic 
effects of bis-quaternary ammonium antimicrobial reagents on human 
cells. Toxicol In Vitro, 2000, 14: 139–147 
61 Cheng G, Xue H, Zhang Z, et al. A switchable biocompatible poly-
mer surface with self-sterilizing and nonfouling capabilities. Angew 
Chem Int Ed, 2008, 47: 8831–8834 
62 Tan H, Peng Z, Li Q, et al. The use of quaternised chitosan-loaded 
PMMA to inhibit biofilm formation and downregulate the viru-
lence-associated gene expression of antibiotic-resistant staphylococ-
cus. Biomaterials, 2010, 33: 365–377 
63 Hochbaum A I, Kolodkin-Gal I, Foulston L, et al. Inhibitory effects 
of D-amino acids on staphylococcus aureus biofilm development. J 
Bacteriol, 2011, 193: 5616–5622 
64 Kolodkin-Gal I, Romero D, Cao S, et al. D-amino acids trigger bio-
film disassembly. Science, 2010, 328: 627–629 
65 Xu H, Liu Y. D-amino acid mitigated membrane biofouling and 
promoted biofilm detachment. J Membr Sci, 2011, 376: 266–274 
 
Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction 
in any medium, provided the original author(s) and source are credited. 
 
 
